BOEHRINGER-INGELHEIM
Boehringer Ingelheim and CDR-Life today announced they have entered into a collaboration and licensing agreement to research and develop antibody fragment-based therapeutics for geographic atrophy (GA). GA is a progressive, irreversible retinal disease that occurs in patients with age-related macular degeneration (AMD) for which there is no current treatment. Together, with Boehringer Ingelheim’s expertise in the therapeutic development of biologics and CDR-Life’s strong know-how in antibody engineering, the two companies will progress CDR-Life’s preclinical candidate, with the aim to preserve sight for patients with GA.
“Partnering with CDR-Life provides Boehringer Ingelheim with the opportunity to collaborate with a team that has a proven track record developing antibody fragment-based therapeutics for retinal diseases,” said Clive R. Wood, Ph.D., Corporate Senior Vice President and Global Head of Discovery Research at Boehringer Ingelheim. “The prospect of losing one’s sight is frightening. We are committed to transformational therapies that have the potential to succeed in preserving the health and vision of patients with retinal diseases, such as geographic atrophy.”
Utilizing antibody fragment-based technology, which retains the specificity of an antibody while significantly reducing the size of the molecule, may have significant advantages over traditional large molecule approaches for the treatment of retinal diseases, such as GA. When applied to the eye via intravitreal injection, high affinity antibody fragment therapies have the potential to reach the retinal pigment epithelial cells where degeneration is known to occur. This precise technology may help decrease the cellular stresses caused by AMD and prevent further loss of sight.
“Boehringer Ingelheim is one of the leading research and development companies in the field of biologics,” said Christian Leisner, Ph.D., Chief Executive Officer at CDR-Life. “This is an exciting partnership that brings together Boehringer Ingelheim’s development expertise and CDR-Life’s innovative antibody fragments to provide hope for people living with a blinding retinal disease. We look forward to advancing this project towards the clinic together with the Boehringer Ingelheim team.”
Boehringer Ingelheim takes a holistic approach to the development of novel retinal disease therapies, targeting key mechanisms in the pathogenesis of retinal diseases. By leveraging existing expertise in oncology, inflammation, neurodegeneration, fibrosis and cardiometabolic diseases, the company has built a comprehensive portfolio of next generation retinal therapy approaches in various stages of development up to Phase 2 in macular degeneration and diabetic retinal diseases.
CDR-Life´s preclinical program utilizing antibody fragment-based technology complements this growing portfolio, providing an innovative approach to treat GA.
Under the terms of the agreement, Boehringer Ingelheim will receive an exclusive, worldwide license to develop certain compounds based on CDR-Life´s technology against a specific target and will be responsible for global development and commercialization. CDR-Life will be eligible to receive up to CHF 474.5 million in upfront and success-based milestone payments, as well as research funding and royalties on sales.
Please click on the following link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/geographicatrophycollabortationwithcdr-life
View source version on businesswire.com: https://www.businesswire.com/news/home/20200513005341/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rimini Street to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 19, 202626.1.2026 19:46:00 CET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™, and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on February 19, 2026. The company will host a conference call and webcast on that date to discuss the fourth quarter and fiscal year 2025 results and the 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126188817/en/ Rimini Street to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 19, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, In
SES Acknowledges Fitch’s Rating Action and Reiterates Deleveraging Plan26.1.2026 19:07:00 CET | Press release
SES S.A. (“SES” or the “Company”), a leading space solutions company, acknowledges the credit rating action announced by Fitch today, which follows the release of SES’ Q3 2025 results and Intelsat integration update. SES continues to be rated investment grade by Fitch with a stable outlook. SES management reiterates that the Company continues to execute on its strategy with a clear plan to strengthen its key credit metrics over time. The Company also has a clear view of the multiple cash generating levers available to it that it believes can substantially support and accelerate the deleveraging plan. SES management will use these levers in a disciplined way and keep investors informed as they deliver on the strategic plan. Consistent with this plan, it remains management’s intention to delever, with a policy objective of reducing adjusted net leverage(1) to at least 3.0x or below. (1) Adjusted net leverage is defined as Adjusted Net Debt divided by Adjusted EBITDA. Adjusted Net Debt is
A2RL Drone Championship Sets the Pace for AI in Autonomous Flight26.1.2026 18:17:00 CET | Press release
TII Racing set the fastest autonomous lap of the Championship, establishing a new benchmark for high-speed, vision-based autonomy MAVLAB secured the multi-drone title, showcasing robust multi-agent autonomy in complex, shared environments Human FPV pilot MinChan Kim narrowly defeated AI competitor in a decisive Human vs AI finale, in a down-to-the-wire showdown The Abu Dhabi Autonomous Racing League (A2RL) Drone Championship delivered a decisive test of autonomous and human performance, as Technology Innovation Institute’s TII Racing set the fastest autonomous lap to win the AI Speed Challenge, while a human first-person-view (FPV) pilot, MinChan Kim – World FPV Champion, narrowly claimed victory in the Human vs AI finale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126735530/en/ A2RL Drone Championship Sets the Pace for AI in Autonomous Flight (Photo: AETOSWire) Organised by ASPIRE, the innovation acceleration arm of
Zayed Sustainability Prize Opens Global Call for Submissions for 2027 Cycle26.1.2026 16:25:00 CET | Press release
With an increased prize fund of US $7.2 million, the Zayed Sustainability Prize supports enterprises, nonprofit organisations and schools delivering transformative solutions.Entries are now open, with applicants invited to submit innovative, scalable sustainability solutions.Now in its 18th year, the Prize has positively impacted over 400 million people by expanding access to clean energy, water, food, healthcare and improving climate resilience. The Zayed Sustainability Prize, an affiliate of Erth Zayed Philanthropies and the UAE’s pioneering global award for sustainability and humanitarian innovation, has opened submissions for its 2027 cycle. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126912976/en/ Winners of the 2026 Zayed Sustainability Prize (Photo: AETOSWire) The Prize carries forward the vision and legacy of the UAE’s founding father, Sheikh Zayed bin Sultan Al Nahyan, by supporting those advancing a more incl
2026 Japan Prize: Two U.S. Scientists and One Japanese Scientist Awarded26.1.2026 15:00:00 CET | Press release
Presentation Ceremony to Take Place in Tokyo in April The Japan Prize Foundation announced the winners of the 2026 Japan Prize at 1:00 p.m. on 21 January 2026. Prof. Cynthia Dwork (USA) has been awarded the Japan Prize in the field of Electronics, Information, and Communication. Prof. Shizuo Akira (Japan) and Prof. Zhijian "James" Chen (USA) have been awarded the Japan Prize in the field of Life Sciences. For this year’s Japan Prize, Prof. Dwork is being recognized for her Contribution to leading research for building an ethical digital society, including differential privacy and fairness. Prof. Akira and Prof. Chen are being recognized for their Discovery of the nucleic acid sensing mechanism by the innate immune system. For the 2026 Japan Prize, the Foundation asked approximately 16,000 prominent scientists and engineers from around the world to nominate researchers working in this year’s fields. We received 107 nominations for the field of Electronics, Information, and Communication
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom